This company listing is no longer active
LDB Stock Overview
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
H. Lundbeck A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.23.02 |
| 52 Week High | kr.27.37 |
| 52 Week Low | kr.19.12 |
| Beta | 0 |
| 1 Month Change | 3.14% |
| 3 Month Change | 10.20% |
| 1 Year Change | -14.04% |
| 3 Year Change | -36.00% |
| 5 Year Change | -55.33% |
| Change since IPO | 21.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| LDB | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.7% | 1.8% |
| 1Y | -14.0% | -24.4% | 5.7% |
Return vs Industry: LDB underperformed the German Pharmaceuticals industry which returned 2.1% over the past year.
Return vs Market: LDB exceeded the German Market which returned -23.8% over the past year.
Price Volatility
| LDB volatility | |
|---|---|
| LDB Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LDB has not had significant price volatility in the past 3 months.
Volatility Over Time: LDB's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1915 | 5,353 | Deborah Dunsire | https://www.lundbeck.com |
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company’s principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson’s disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer’s disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington’s disease, as well as other products.
H. Lundbeck A/S Fundamentals Summary
| LDB fundamental statistics | |
|---|---|
| Market cap | €4.59b |
| Earnings (TTM) | €149.09m |
| Revenue (TTM) | €2.20b |
30.5x
P/E Ratio2.1x
P/S RatioIs LDB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LDB income statement (TTM) | |
|---|---|
| Revenue | kr.16.40b |
| Cost of Revenue | kr.3.51b |
| Gross Profit | kr.12.89b |
| Other Expenses | kr.11.78b |
| Earnings | kr.1.11b |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 17, 2022
| Earnings per share (EPS) | 1.12 |
| Gross Margin | 78.59% |
| Net Profit Margin | 6.76% |
| Debt/Equity Ratio | 32.2% |
How did LDB perform over the long term?
See historical performance and comparison